Transarterial chemoembolisation in hepatocellular carcinoma;Transarterielle perkutane Chemoembolisation beim Leberzellkarzinom

Wiener Medizinische Wochenschrift

Volumn 163, Issue 5-6, 2013, Pages 123-127

  Petersen, Johannes ^a   Henninger, Benjamin ^a   Glodny, Bernhard ^a   Jaschke, Werner ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Angiography; Bland embolisation; Drug eluting bead doxorubicin; Hepatocellular carcinoma; Transarterial chemoembolisation

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; MICROSPHERE;

ARTICLE; CANCER SURVIVAL; CHEMOEMBOLIZATION; LIVER CELL CARCINOMA; PATIENT HISTORY OF LIVER TRANSPLANTATION; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; ANGIOGRAPHY; CANCER STAGING; COOPERATION; HUMAN; INTERDISCIPLINARY COMMUNICATION; LIVER TUMOR; MORTALITY; PALLIATIVE THERAPY; PATHOLOGY; PROGNOSIS; REVIEW; SURVIVAL RATE; TUMOR INVASION; VASCULARIZATION;

ANGIOGRAPHY; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COOPERATIVE BEHAVIOR; DOXORUBICIN; HUMANS; INTERDISCIPLINARY COMMUNICATION; LIVER NEOPLASMS; MICROSPHERES; NEOPLASM INVASIVENESS; NEOPLASM STAGING; PALLIATIVE CARE; PROGNOSIS; SURVIVAL RATE;

EID: 84885582748     PISSN: 00435341     EISSN: 1563258X     Source Type: Journal    
DOI: 10.1007/s10354-013-0180-x     Document Type: Article

References (29)

1. Khan SA, Taylor-Robinson SD, Toledano MB, Beck A, Elliott P, Thomas HC. Changing international trends in mortality rates for liver, biliary and pancreatic tumors. J Hepatol. 2002;37:805-13.
2. Poon RTP, Fan ST, Wong J. Risk factors, prevention and management of postoperative recurrence after resection of hepatocellular carcinoma. Ann Surg. 2000;232:10-24.
3. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis. 1999;19:329-38.
4. Cho YK, Kim WT, Chung JW. Hepatic resection versus radiofrequency ablation for very early stage hepatocellular carcinoma in cirrhosis: is resection still the treatment of choice? Hepatology. 2010;51:1116-8.
5. Llovet JM, Burroghs A, Bruix J. Hepatocellular Carcinoma. Lancet. 2003;362:1907-17.
6. Clark HP, Carson WF, Kavanagh PV, Ho CP, Shen P, Zagoria RJ. Staging and current treatment of hepatocellular carcinoma. Radiographics. 2005;25(Suppl):3-23.
7. Wible BC, Rilling WS, Drescher P, Hieb RA, Saeian K, Frangakis C, Chen Y, Eastwood D, Kim HS. Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol. 2010;21:1024-30.
8. Majno PE, Adam R, Bismuth H, Castaing D, Ariche A, Krissat J, Perrin H, Azoulay D. Influence of preoperative transarterial lipiodol chemoembolizationon resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg. 1997;226:688-701.
9. Sugo H, Futagawa S, Beppu T, Fukasawa M, Kojima K. Role of preoperative transcatheter arterial chemoembolization for resectable hepatocellular carcinoma: relation between postoperative course and the pattern of tumor recurrence. World J Surg. 2003;27:1295-9.
10. Graziadei IW, Sandmueller H, Waldenberger P, Koenigsrainer A, Nachbaur K, Jaschke W, Margreiter R, Vogel W. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl. 2003;9:557-63.
11. Marelli L, Stigliano R, Triantos C, Senzolo M, Cholongitas E, Davies N, Tibballs J, Meyer T, Patch DW, Burroughs AK. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol. 2007;30:6-25.
12. Vogl TJ, Trapp M, Schroeder H, Mack M, Schuster A, Schmitt J, Neuhaus P, Felix R. Transarterial chemoembolization for hepatocellular carcinoma: volumetric and morphologic CT criteria for assessment of prognosis and therapeutic success-results from a liver transplantation center. Radiology. 2000;214:349-57.
13. Bonomo G, Pedicini V, Maonfardini L, Della Vigna P, Poretti D, Orgera G, Orsi F. Bland embolization in patients with unresectable hepatocellular carcinoma using precise, tightly size-calibrated, anti-inflammatory microparticles: first clinical experience and one-year follow-up. Cardiovasc Intervent Radiol. 2010;33:552-9.
14. Lammer J, Malagari K, Vogl TJ, Pilleul F, Denys A, Watkinson A, Pitton M, Sergent G, Pfammatter T, Terraz S, Benhamou Y, Avajon Y, Gruenberger T, Pomoni M, Langenberger H, Schuchmann M, Dumortier J, Mueller C, Chevallier P, Lencioni R; PRECISION V Investigators. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol. 2010;33;41-52.
15. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, Denys A, Lee C. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinoma treated with PRECISION TACE with drug-eluting beads: results from the PRECISION V randomized trial. Am J Roentgenol. 2011;197:W562-70.
16. Malagari K, Pomoni M, Moschouris H, Bouma E, Koskinas J, Stefaniozou A, Marinis A, Kelekis A, Alexopoulou E, Chatziioannou A, Chatzimichael K, Dourakis S, Kelekis N, Rizos S, Kelekis D. Chemoembolization with doxurubicineluting beads for unresectable hepatocellular carcinoma: five-year survival analysis. Cardiovasc Intervent Radiol. 2012; Epub ahead of print.
17. Lencioni R, de Baere T, Burrel M, Caridi JG, Lammer J, Malagari K, Martin RC, O'Grady E, Real MI, Vogl TJ, Watkinson A, Geschwind JF. Transcatheter treatment of hepatocellular carcinoma with doxorubicin-loaded DC bead (DEBDOX): technical recommendations. Cardiovasc Intervent Radiol. 2011; Epub ahead of print.
18. Lee JK, Chung YH, Song BC, Shin JW, Choi WB, Yang SH, Yoon HK, Sung KB, Lee YS, Suh DJ. Recurrences of hepatocellular carcinoma following initial remission by transcatheter arterial chemoembolization. J Gastroenterol Hepatol. 2002;17:52-8.
19. Grieco A, Marcoccia S, Miele L, Marmirol L, Caminiti G, Ragazzoni E, Cotroneo AR, Cefaro GA, Rapaccini GL, Gasbarrini G. Transarterial chemoembolization (TACE) for unresectable hepatocellular carcinoma in cirrhotics: functional hepatic reserve and survival. Hepato-gastroenterol 2003;50:207-12.
20. Rossi S, Garbagnati F, Lencioni R, Allgaier HP, Marchianò A, Fornari F, Quaretti P, Tolla GD, Ambrosi C, Mazzaferro V, Blum HE, Bartolozzi C. Percutaneous radio-frequency thermal ablation of non-resectable hepatocellular carcinoma after occlusion of tumor supply. Radiology. 2000;217:119-26.
21. Takamura M, Murakami T, Shibata T, Ishida T, Niinobu T, Kawata S, Shimizu J, Kim T, Monden M, Nakamura H. Microwave coagulation therapy with interruption of hepatic blood in- or outflow: an experimental study. J Vasc Interv Radiol. 2001;12:619-22.
22. Gerunda GE, Neri D, Merenda R, Barbazza F, Zangrandi F, Meduri F, Bisello M, Valmoasoni M, Gangemi A, Faccioli AM. Role of transarterial chemoembolization before liver resection for hepatocarcinoma. Liver Transpl. 2000;6:619-26.
23. Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F. Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324-31.
24. Gray B, Van Hazel G, Hope M, Burton M, Moroz P, Anderson J, Gebski V. Randomised trial of SIR-spheres plus chemotherapy vs. chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann Oncol. 2001;12:1711-20.
25. Soulen MC. Image-guided therapy of hepatic malignancies. Appl Radiol. 2000;29:21-2.
26. Leung DA, Goin JE, Sickles C, Raskay BJ, Soulen MC. Determinants of postembolization syndrome after hepatic chemoembolization. J Vasc Interv Radiol. 2001;12:321-26.
27. Patel NH, Hahn D, Rapp S, Bergan K, Coldwell DM. Hepatic artery embolization: factors predisposing to postembolization pain and nausea. J Vasc Interv Radiol. 2000;11:453-60.
28. Llovet JM, Fuster J, Bruix J. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl. 2004;10:115-20.
29. Grieco A, Pompili M, Caminiti G, Miele L, Covino M, Alfei B, Rapaccini GL, Gasbarrini G. Prognostic factors for survival in patients with early-intermediate hepatocellular carcinoma undergoing non-surgical therapy: comparison of Okuda, CLIP, and BCLC staging systems in a single Italian centre. Gut. 2005;54:411-8.